<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017872</url>
  </required_header>
  <id_info>
    <org_study_id>D2EFT</org_study_id>
    <nct_id>NCT03017872</nct_id>
  </id_info>
  <brief_title>Dolutegravir and Darunavir Evaluation in Adults Failing Therapy</brief_title>
  <acronym>D²EFT</acronym>
  <official_title>A Phase IIIB/IV Randomised Open-label Trial to Compare Dolutegravir + Pharmaco-enhanced Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in Patients With HIV Infection Who Have Failed Recommended First Line Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNITAID</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line
      antiretroviral therapy (ART). The study compares a novel regimen of second-line ART
      (dolutegravir and darunavir pharmaco-enhanced with ritonavir) with the WHO recommended
      regimen of 2(t)NRTIs plus a ritonavir-boosted PI (Standard of Care (SOC)). 610 participants
      from 10 predominantly low-middle income countries will be followed for 96 weeks with the
      primary endpoint at week 48. The design is based on the hypothesis that the new regimen will
      be non-inferior to SOC in terms of virologic control while being easier to take, economically
      viable and affording simplification of treatment programs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting participants will be screened and within 45 days randomly allocated to receive
      either dolutegravir and darunavir/ritonavir or the SOC regimen. Participants will be seen
      four weeks after their randomisation (week 0) visit and then at weeks 24, 48 and 96.
      Consenting participants will have storage samples collected and cryopreserved at their week
      0, 48 &amp; 96 visits. This repository will be used in future for central baseline resistance
      testing, pharmacogenomic testing (separate consent required) and has inherent value for later
      studies of HIV pathogenesis. A 1-time PK sample will be collected at week four for future
      testing and any participants failing therapy at 24 weeks will have a plasma sample stored for
      future genotypic resistance testing.

      A number of secondary outcomes will be considered in order to compare the performance of the
      two study treatment regimens. Secondary analyses will focus on virological, immunological,
      safety, antiretroviral treatment change and medication adherence. A comparison of costs and
      estimates of cost-effectiveness for the randomised comparison will be a critical component of
      this study. ART costs will be assessed across study arms. Health-care utilisation will be
      self-reported and then used to estimate costs. Safety data, viral loads and quality of life
      data will also be analysed.

      The open label nature of the study allows routine care to be undertaken and the use of
      objective endpoints limit potential bias. The study has well defined and integrated clinical
      data collection and patient management systems that have been shown to be effective in a wide
      range of clinical settings.

      The choice of N(t)RTIs in the SoC regimen is based on clinical judgement and may be guided by
      resistance testing if locally available. The NRTIs are not provided via the study. At the end
      of 96 weeks (completion of the protocol) study drug can be offered to all participants for a
      further 48 weeks as informed by the 48-week study results and clinical judgement. After 144
      weeks study drug will no longer be available and composition of the participant's post-study
      regimen will be the clinician's decision.'
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants in each arm whose plasma viral load is &lt;50 copies/mL at 48 weeks by intention to treat.</measure>
    <time_frame>At 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion with plasma viral load &lt;200 copies/mL</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with plasma viral load &lt;50 copies/mL where those stopping randomised therapy for any reason are classified as plasma viral load &gt;50 copies/mL</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CD4+ cell count from baseline</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median changes from baseline in fasted lipids (Total cholesterol, LDL-c, HDL-c, and triglycerides)</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of participants with any serious adverse events (SAEs), and the cumulative incidence of SAEs</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of opportunistic diseases (AIDS events), deaths and serious non-AIDS defining events and the cumulative incidence of these</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with cessation of randomly assigned therapy</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorisation of neuropsychological adverse events</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion who stopped randomised therapy by reason for stopping</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of genotypic HIV resistance associated with virological failure</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence assessment using participant 7-day recall self-report questionnaire</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and anxiety &amp; depression assessed by participant questionnaire</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilisation assessed by participant questionnaire</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of care assessment</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">610</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SoC) arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x NRTIs + darunavir/ritonavir 800mg/100mg po od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N(t)RTIs</intervention_name>
    <description>Choice of N(t)RTI determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.</description>
    <arm_group_label>Standard of Care (SoC) arm</arm_group_label>
    <other_name>Nucleoside/Nucleotide Reverse Transcription Inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>50mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>Dolutegravir arm</arm_group_label>
    <other_name>Tivicay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>800mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>Standard of Care (SoC) arm</arm_group_label>
    <arm_group_label>Dolutegravir arm</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>100mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>Standard of Care (SoC) arm</arm_group_label>
    <arm_group_label>Dolutegravir arm</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 positive by licensed diagnostic test

          2. Aged ≥16 years of age (or minimum age as determined by local regulations or as legal
             requirements dictate)

          3. Failed first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) + 2N(t)RTI
             combination therapy according to virological criteria, defined as at least two
             consecutive (≥7 days apart) pVL results &gt;500 copies/mL after a minimum period of
             exposure to continuous NNRTI + 2N(t)RTI first-line therapy of 24 weeks (only the
             second pVL result needs to be within 45 days of randomisation)

          4. Able to provide written informed consent

        Exclusion Criteria:

          1. The following laboratory variables:

               1. absolute neutrophil count (ANC) &lt;500 cells/µL

               2. haemoglobin &lt;7.0 g/dL

               3. platelet count &lt;50,000 cells/µL

               4. AST and/or ALT ≥5xULN OR ALT ≥3xULN and bilirubin ≥1.5xULN (with &gt;35% direct
                  bilirubin)

          2. Change in antiretroviral therapy within 12 weeks prior to randomisation

          3. Prior exposure to HIV protease inhibitors and/or HIV integrase inhibitors

          4. Patients with chronic viral hepatitis B infection defined by positive serum hepatitis
             B surface antigen

          5. Unstable liver disease (as defined by the presence of ascites, encephalopathy,
             coagulopathy (INR &gt;2.3), hypoalbuminemia (serum albumin &lt;2.8g/dL), esophageal or
             gastric varices, or persistent jaundice), known biliary abnormalities (with the
             exception of Gilbert's syndrome or asymptomatic gallstones)

          6. Anticipated need for Hepatitis C virus (HCV) therapy with interferon during the study

          7. Subject has creatinine clearance of &lt;50 mL/min via CKD-EPI equation

          8. Current use of rifabutin or rifampicin

          9. Use of any contraindicated medications (as specified by product information sheets)

         10. Intercurrent illness requiring hospitalization

         11. An active opportunistic disease not under adequate control in the opinion of the
             investigator

         12. Pregnant or nursing mothers

         13. Patients with current alcohol or illicit substance use that in the opinion of the
             investigator might adversely affect participation in the study

         14. Patients deemed unlikely by the investigator to be able to remain in follow-up for the
             protocol-defined period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Cooper</last_name>
    <role>Study Director</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone S Jacoby</last_name>
    <phone>+61 2 9385 0900</phone>
    <phone_ext>50919</phone_ext>
    <email>sjacoby@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital G de Agudos JM Ramos Mejia</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad De Buenos Aires</state>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcelo Losso</last_name>
      <phone>5411 4127 0276</phone>
      <email>mlosso@hivramos.org.ar</email>
    </contact>
    <contact_backup>
      <last_name>Guillermo Viloria</last_name>
      <phone>5411 4931 5252</phone>
      <email>gviloria@hivramos.org.ar</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo Losso, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Prof Alejandro Posadas</name>
      <address>
        <city>El Palomar</city>
        <state>Provincia De Buenos Aires</state>
        <zip>1684</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Esther Daciuk, M.D.</last_name>
      <phone>54 11 1544962605</phone>
      <email>luciadaciuk@yahoo.com.ar</email>
    </contact>
    <contact_backup>
      <last_name>Hector Laplume, M.D.</last_name>
      <phone>54 11 1560426461</phone>
      <email>hectorlaplume@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lucia Esther Daciuk, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Diego Paroissien</name>
      <address>
        <city>Isidro Casanova</city>
        <state>Provincia De Buenos Aires</state>
        <zip>1765</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo Warley</last_name>
      <phone>5411 1541 897 181</phone>
      <email>eduwarley@yahoo.com.ar</email>
    </contact>
    <contact_backup>
      <last_name>Maria Ines Vieni</last_name>
      <phone>5411 1136 877 377</phone>
      <phone_ext>3340</phone_ext>
      <email>inesvieni@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eduardo Warley, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAICI</name>
      <address>
        <city>Rosario</city>
        <state>Provincia De Santa Fe</state>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Lupo</last_name>
      <phone>54 9 341 515 7704</phone>
      <email>drsergiolupo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Luciana Peroni</last_name>
      <phone>54 341 424 8045</phone>
      <email>administracioncaici@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sergio Lupo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal de Agudos San Juan de Dios</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Michaan</last_name>
      <phone>+54 9221 5765 131</phone>
      <email>mgmichaan@yahoo.com.ar</email>
    </contact>
    <investigator>
      <last_name>Martha Michaan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Borja-Arriaran</name>
      <address>
        <city>Santiago</city>
        <zip>8360159</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcelo Wolff</last_name>
      <phone>562- 555 6206</phone>
      <email>marcewolff@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Gladys Allendes</last_name>
      <phone>562-555-6206</phone>
      <email>gladys_allendes@yahoo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo Wolff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASISTENCIA Cientifica De Alta Complejidad S.A.S.</name>
      <address>
        <city>Bogota</city>
        <zip>110010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Otto Sussmann</last_name>
      <phone>57-1- 5107600</phone>
      <phone_ext>104</phone_ext>
      <email>osussmann@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana Julia Rojas</last_name>
      <phone>57-1-5107600</phone>
      <phone_ext>128</phone_ext>
      <email>coord.investigaciones@asistenciacientifica.com</email>
    </contact_backup>
    <investigator>
      <last_name>Otto Sussmann, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>YRG Care</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nagalingeswaran Kumarasamy</last_name>
      <phone>91 917 691 2007</phone>
      <email>kumarasamy@yrgcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Faith Beulah</last_name>
      <phone>91 44 39106811</phone>
      <email>beulah@yrgcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nagalingeswaran Kumarasamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raja Iskandar Shah Raja Azwa</last_name>
      <phone>603-79493834</phone>
      <email>iskandar.azwa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Tan</last_name>
      <phone>603-79492622</phone>
      <email>margarettan455@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Raja Iskandar Shah Raja Azwa, MBChB, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morales Vargas Centro de Investigacion SC</name>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Luis Mosqueda Gomez</last_name>
      <phone>+52 (477) 1310037</phone>
      <email>luis_mosqueda@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Jorge Morales Vargas</last_name>
      <phone>+52 (477) 7160714</phone>
      <email>mnc.jorge@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaime Andrade-Villanueva</last_name>
      <email>jandradev@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Angeles González-Hernández</last_name>
      <phone>5233 3614 7586</phone>
      <email>angelesghdez1@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jaime Andrade-Villanueva, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Sierra Madero</last_name>
      <phone>52 5556559675</phone>
      <email>jsmadero@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Izchel Loyo</last_name>
      <email>iz.inncm@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Juan Sierra Madero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Kaplan</last_name>
      <email>Richard.Kaplan@hiv-research.org.za</email>
    </contact>
    <contact_backup>
      <last_name>Christie Heiberg</last_name>
      <phone>27 21 406 3621</phone>
      <email>Christie.Heiberg@hiv-research.org.za</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Kaplan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical HIV Research Unit (CHRU), Wits Health Consotium (Pty) Ltd</name>
      <address>
        <city>Johannesburg</city>
        <zip>2041</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noluthando Mwelase</last_name>
      <email>tmwelase@witshealth.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Pauline Vunandala</last_name>
      <phone>27 11 276 8800</phone>
      <email>pvunandlala@witshealth.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Noluthando Mwelase, MBCHB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lerato Mohapi</last_name>
      <email>mohapil@hivsa.com</email>
    </contact>
    <contact_backup>
      <last_name>Debra Peters</last_name>
      <phone>27 11 989 9700</phone>
      <email>petersd@phru.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Lerato Mohapi, BSc, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anchalee Avihingsanon</last_name>
      <phone>+662 652 3040</phone>
      <phone_ext>107</phone_ext>
      <email>anchaleea2009@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kanitta Pussadee</last_name>
      <phone>+662 652 3040</phone>
      <phone_ext>202</phone_ext>
      <email>kanitta.p@hivnat.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anchalee Avihingsanon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pacharee Kantipong</last_name>
      <phone>66818859195</phone>
      <email>pachareek@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Supawadee Pongprapass</last_name>
      <phone>66819616900</phone>
      <email>npudit@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pacharee Kantipong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ploenchan Chetchotisakd</last_name>
      <phone>6643363168</phone>
      <email>ploencha@kku.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Anchalee Tiyabut</last_name>
      <phone>6643363169</phone>
      <email>atiyabut@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ploenchan Chetchotisakd, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weerawat Manosuthi</last_name>
      <email>drweerawat@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Supeda Thongyen</last_name>
      <phone>6625903631</phone>
      <email>supeda_t@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Weerawat Manosuthi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe Clinical Research Centre</name>
      <address>
        <city>Harare</city>
        <zip>+263</zip>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James G Hakim</last_name>
      <phone>263 772225489</phone>
      <email>Jhakim@mweb.co.zw</email>
    </contact>
    <contact_backup>
      <last_name>Shepherd Mudzingwa</last_name>
      <phone>263 4 701717</phone>
      <email>smudzingwa@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>James G Hakim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV, second-line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

